# TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation

> **NCT07634562** · PHASE1,PHASE2 · RECRUITING · sponsor: **Stanford University** · enrollment: 12 (estimated)

## Conditions studied

- Liver Failure

## Interventions

- **DRUG:** Anti-Thymocyte Globulin, ATG (Rabbit)
- **DEVICE:** Total lymphoid irradiation

## Key facts

- **NCT ID:** NCT07634562
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2031-08
- **Final completion:** 2031-08
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634562, "TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07634562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*